Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 4, 2013, Pages 203-213

  Morin, Caroline ^a,b   Rousseau, Éric ^b   Fortin, Samuel ^a  

^a SCF Pharma   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Apoptosis; Colorectal carcinoma; DPA; NF B

Indexed keywords

CD31 ANTIGEN; CYCLIN D1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID MONOGLYCERIDE; DOCOSAPENTAENOIC ACID MONOGLYCERIDE; EICOSAPENTAENOIC ACID MONOGLYCERIDE; GELATINASE B; MYC PROTEIN; POLYUNSATURATED FATTY ACID; PROTEIN BCL 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CELL STRAIN HCT116; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

APOPTOSIS; COLORECTAL CARCINOMA; DPA; NFΚB;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FATTY ACIDS; FEMALE; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIPID METABOLISM; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MONOGLYCERIDES; NF-KAPPA B; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884530545     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.07.004     Document Type: Article

References (59)

1. Greenlee R.T., Murray T, Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer. J. Clin. 2000, 50:7-33.
2. Parkin D.M., Olsen A.H., Sasieni P. The potential for prevention of colorectal cancer in the UK. Eur. J. Cancer Prev 2009, 18:179-190.
3. Hall M.N., Campos H., Li H., Sesso H.D., Stampfer M.J., Willett W.C., et al. Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prevent. 2007, 16:314-321.
4. Patterson R.E., Flatt S.W., Newman V.A., Natarajan L., Rock C.L., Thomson C.A., et al. Marine fatty acid intake is associated with breast cancer prognosis. J. Nutr. 2011, 141:201-206.
5. Hall M.N., Chavarro J.E., Lee I.M., Willett W.C., Ma J. A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol. Biomarkers Prevent. 2008, 17:1136-1143.
6. McEntee M.F., Ziegler C., Reel D., Tomer K, Shoieb A., Ray M., et al. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. Am. J. Pathol. 2008, 173:229-241.
7. Kato T., Kolenic N., Pardini R.S. Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status. Nutr. Cancer 2007, 58:178-187.
8. Siddiqui R.A., Shaikh S.R., Sech L.A., Yount H.R., Stillwell W., Zaloga G.P. Omega 3-fatty acids: health benefits and cellular mechanisms of action. Mini-Rev. Med. Chem. 2004, 4:859-871.
9. Dommels Y.E., Heemskerk S., Van Den Berg H., Alink G.M., van Bladeren P.J., van Ommen B. Effects of high fat fish oil and high fat corn oil diets on initiation of AOM-induced colonic aberrant crypt foci in male F344 rats. Food Chem. Toxicol. 2003, 41:1739-1747.
10. Latham P., Lund E.K., Johnson I.T. Dietary n-3 PUFA increases the apoptotic response to 1,2-dimethylhydrazine, reduces mitosis and suppresses the induction of carcinogenesis in the rat colon. Carcinogenesis 1999, 20:645-650.
11. Geelen A., Schouten J.M., Kamphuis C., Stam B.E., Burema J., Renkema J.M., et al. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. Am. J. Epidemiol. 2007, 166:1116-1125.
12. Larsson S.C., Kumlin M., Ingelman-Sundberg M., Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr. 2004, 79:935-945.
13. Christiansen E.N., Lund J.S., Rortveit T., Rustan A.C. Effect of dietary n-3 and n-6 fatty acids on fatty acid desaturation in rat liver. Biochim. Biophys. Acta. 1991, 1082:57-62.
14. Chang W.L., Chapkin R.S., Lupton J.R. Fish oil blocks azoxymethane-induced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. J. Nutr. 1998, 128:491-497.
15. Llor X., Pons E., Roca A., Alvarez M., Mane J., Fernandez-Banares F., et al. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin. Nutr. 2003, 22:71-79.
16. Narayanan B.A., Narayanan N.K., Reddy B.S. Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. Int. J. Oncol. 2001, 19:1255-1262.
17. Kaur G., Cameron-Smith D., Garg M., Sinclair A.J. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog. Lipid Res. 2011, 50:28-34.
18. Phang M., Garg M.L., Sinclair A.J. Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specific-Redefining platelet response to fish oils. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81:35-40.
19. Kaur G., Sinclair A.J., Cameron-Smith D., Barr D.P., Molero-Navajas J.C., Konstantopoulos N. Docosapentaenoic acid (22:5n-3) down-regulates the expression of genes involved in fat synthesis in liver cells. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85:155-161.
20. Gotoh N., Nagao K., Onoda S., Shirouchi B., Furuya K., Nagai T., et al. Effects of three different highly purified n-3 series highly unsaturated fatty acids on lipid metabolism in C57BL/KsJ-db/db mice. J. Agric. Food Chem. 2009, 57:11047-11054.
21. Kishida G.E., Tajiri M., Masuzawa Y. Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor. Biochim. Biophys. Acta 2006, 1761:454-462.
22. Miller E., Kaur G., Larsen A., Loh S.P., Linderborg K., Weisinger H.S., et al. A short-term n-3 DPA supplementation study in humans. Eur. J. Nutr. 2012, 52, 2013, 895-904.
23. Kaur G., Molero J.C., Weisinger H.S., Sinclair A.J. Orally administered [14C]DPA and [14C]DHA are metabolised differently to [14C]EPA in rats. Br. J. Nutr 2012, 11:1-8.
24. Schuchardt J.P., Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2013, 89, 2013, 1-8.
25. Dyerberg J., Madsen P., Møller J.M., Aardestrup I., Schmidt E.B. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot. Essent. Fatty Acids 2010, 83:137-141.
26. Cruz-Hernandez C., Thakkar S.K., Moulin J., Oliveira M., Masserey-Elmelegy I., Dionisi F., Destaillats F Benefits of structured and free monoacylglycerols to deliver eicosapentaenoic (EPA) in a model of lipid malabsorption. Nutrients 2012, 4:1781-1793.
27. S. Fortin, Polyunsaturated Fatty Acid Monoglycerides, Derivatives, and Uses thereof, CA2672513 (2008), CA2677670 (2010), US8119690 (2011).
28. S. Fortin, Compositions Comprising Polyunsaturated Fatty Acid Monoglycerides or Derivatives thereof and Uses thereof, US819690 (2012), US8222295 (2012).
29. Dobson E.P., Barrow C.J., Kralovec J.A., Adcock J.L. Controlled formation of mono- and dihydroxy-resolvins from EPA and DHA using soybean 15-lipoxygenase. J. Lipid Res. 2013, 54(5):1439-1447.
30. Morin C., Fortin S., Cantin A.M., Sirois M., Sirois C., Riscallah E., et al. Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Pat. Anticancer Drug Discovery 2013, 8, 2013, 319-334.
31. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
32. Gagne S., Crane S., Huang Z., Li C.S., Bateman K.P., Levesque J.F. Rapid measurement of deuterium-labeled long-chain fatty acids in plasma by HPLC-ESI-MS. J. Lipid Res. 2007, 48:252-259.
33. Wang S., Liu Z., Wang L., Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell. Mol. Immunol. 2009, 6:327-334.
34. Akiba S., Murata T., Kitatani K., Sato T. Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation. Biol. Pharm. Bull. 2000, 23:1293-1297.
35. Holub B.J., Swidinsky P., Park E. Oral docosapentaenoic acid (22:5n-3) is differentially incorporated into phospholipid pools and differentially metabolized to eicosapentaenoic acid in tissues from young rats. Lipids 2011, 46:399-407.
36. Christensen E., Woldseth B., Hagve T.A., Poll-The B.T., Wanders R.J., Sprecher H., et al. Peroxisomal beta-oxidation of polyunsaturated long chain fatty acids in human fibroblasts. The polyunsaturated and the saturated long chain fatty acids are retroconverted by the same acyl-CoA oxidase. Scand. J. Clin. Lab. Invest. 1993, Suppl. 215:61-74.
37. Stoffel W., Eker H., Assad H. Sprecher, Enzymatic studies on the mechanism of the retroconversion of C22-polyenoic fatty acids to their C20-homologues. Hoppe-Seyler's Z. Physiol. Chem. 1970, 351:1545-1554.
38. Kaur G., Begg D.P., Barr D., Garg M., Cameron-Smith D., Sinclair A.J. Short-term docosapentaenoic acid (22:5 n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats. Br. J. Nutr. 2010, 103:32-37.
39. Palakurthi S.S., Flückiger R., Aktas H., Changolkar A.K., Shahsafaei A., Harneit S., Kilic E., Halperin J.A. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. 2000, 60:2919-2925.
40. Dommels Y.E., Haring M.M., Keestra N.G., Alink G.M., van Bladeren P.J., van Ommen B. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 2003, 24:385-392.
41. Schønberg S.A., Lundemo A.G., Fladvad T., Holmgren K., Bremseth H., Nilsen A., Gederaas O., Tvedt K.E., Egeberg K.W., Krokan H.E. Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1. FEBS J. 2006, 273:2749-2765.
42. Calviello G., Resci F., Serini S., Piccioni E., Toesca A., Boninsegna A., Monego G., Ranelletti F.O., Palozza P. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 2007, 28:1202-1209.
43. Giros A., Grzybowski M., Sohn V.R., Pons E., Fernandez-Morales J., Xicola R.M., Sethi P., Grzybowski J., Goel A., Boland C.R., Gassull M.A., Llor X. Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic. Cancer Prev. Res. 2009, 2:732-742.
44. Bégin M.E., Ells G. Effects of C18 fatty acids on breast carcinoma cells in culture. Anticancer Res. 1987, 7:215-217.
45. Brekke O.L., Espevik T., Bardal T., Bjerve K.S. Effects of n-3 and n-6 fatty acids on tumor necrosis factor cytotoxicity in WEHI fibrosarcoma cells. Lipids 1992, 27:161-168.
46. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
47. Voboril R., Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 2006, 53:518-523.
48. Lind D.S., Hochwald S.N., Malaty J., Rekkas S., Hebig P., Mishra G., et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001, 130:363-369.
49. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 2006, 72:1161-1179.
50. Maeda S., Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer. Sci. 2008, 99:836-842.
51. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cells 2004, 6:203-208.
52. Yam D., Peled A., Shinitzky M. Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother. Pharmacol. 2001, 47:34-40.
53. de Bravo M.G., de Antueno R.J., Toledo J., De Tomas M.E., Mercuri O.F., Quintans C. Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids 1991, 26:866-870.
54. Krishnamoorthy S., Honn K.V. Eicosanoids in tumor progression and metastasis. Subcell. Biochem. 2008, 49:145-168.
55. Jia Q., Shi Y., Bennink M.B., Pestka J.J. Docosahexaenoic acid and eicosapentaenoic acid, but not alpha-linolenic acid, suppress deoxynivalenol-induced experimental IgA nephropathy in mice. J. Nutr. 2004, 134:1353-1361.
56. Okuyama H., Kobayashi T., Watanabe S. Dietary fatty acids-the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Prog. Lipid Res. 1996, 35:409-457.
57. Pawar A., Jump D.B. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J. Biol. Chem. 2003, 278:35931-35939.
58. Benistant C., Achard F., Ben Slama S., Lagarde M. Docosapentaenoic acid (22:5,n-3): metabolism and effect on prostacyclin production in endothelial cells. Prostaglandins Leukot. Essent. Fatty Acids 1996, 55:287-292.
59. Rosenthal M.D., Garcia M.C., Jones M.R., Sprecher H. Retroconversion and delta 4 desaturation of docosatetraenoate (22:4(n-6)) and docosapentaenoate (22:5(n-3)) by human cells in culture. Biochim. Biophys. Acta 1991, 1083:29-36.